HOME > News > Press Releases > 2024.4.2 Glac Biotech’s Probiotic Strains F-1 & CP-9 — The Secret Engine Powering Global OEM Success

News

2024.4.2 Glac Biotech’s Probiotic Strains F-1 & CP-9 — The Secret Engine Powering Global OEM Success

Share to
Not long ago, many health supplement manufacturers in Taiwan faced the same challenge: demand for probiotics was soaring, but stable supply and reliable strains were hard to secure. Orders from around the world were pouring in, yet ensuring consistency in quality was another story.
That’s where Glac Biotech stepped in. With world-class probiotic production facilities and nearly two decades of scientific dedication, Glac offered something rare: strains with both high stability and proven performance. Among its portfolio, two stars stood out — Bifidobacterium lactis CP-9 and Lactobacillus rhamnosus F-1. These strains became the very reason global OEM partners could accept orders with confidence, knowing their products would deliver consistent quality to consumers in nearly 30 countries, reaching more than 1.4 billion people worldwide.

Meeting the Needs of Key Markets: Women, Weight, and Immunity
The health supplement industry has long focused on three booming categories: women’s health, weight management, and immunity. What makes CP-9 and F-1 so powerful is their versatility across all three — and across all age groups, from children to adults to seniors. For OEM manufacturers, that means freedom: the ability to use a single strain to serve multiple market needs.
The high resilience, stability, and strong cost-effectiveness of these strains have made them the backbone of numerous best-selling formulations. In other words, CP-9 and F-1 don’t just perform in the lab — they empower partners to build products consumers trust.

Science and Recognition on a Global Stage
Glac’s renowned Bifidobacterium lactis CP-9, derived from healthy breast milk, has shown through research that it helps maintain a balanced gut microbiome, supports antioxidant defenses, and regulates immune function. These strengths have earned CP-9 recognition at the prestigious NutraIngredients Awards, often called the “Oscars” of the nutrition industry. Today, CP-9 holds 14 functional patents worldwide.
Meanwhile, Lactobacillus rhamnosus F-1 has become a go-to choice for women’s health solutions, already widely applied in leading supplements designed to support female wellness. Together, CP-9 and F-1 have contributed to thousands of scientific publications, and with Glac’s proprietary production technologies — multiple patented processes ensuring safety and potency — they stand out as the most reliable tools for OEM manufacturers.

Unlocking Market Opportunities for Partners
The success of CP-9 and F-1 isn’t just about scientific achievement; it’s about opening doors. These strains have become growth engines for OEM factories, helping them capture opportunities in fast-growing segments and secure stable orders from around the world.
For brands seeking to expand in competitive health markets, the story is clear: Glac Biotech’s F-1 and CP-9 are more than ingredients — they are keys to unlocking new categories, new customers, and new revenue streams.

If you’d like to explore how these two world-class strains can elevate your products and set you apart in women’s health, weight management, and immunity, we welcome you to connect with Glac Biotech. The next success story could be yours.
 

Media Coverage (Extended Reading)

Previous Back to list Next
Back
TOP